Search Results

or without bevacizumab. This is based on the results of the TRIBE study that showed FOLOXIRI/bevacizumab produced a 4-month advantage in overall survival (OS) versus FOLFIRI/bevacizumab ( P =.03). 3 , 4 “It doesn't, however, increase your ability to

and bevacizumab have made a profound difference in progression-free survival (PFS) for patients with ovarian cancer. All patients should have genetic testing and be treated accordingly. The potential for cure is on the horizon,” he added. Dr. O

provide confirmatory evidence supporting the original ECOG 2100 study that had led to accelerated approval of bevacizumab in combination with paclitaxel for advanced breast cancer. The FDA will decide in September whether to withdraw the label for the

may be just as effective.” Because median OS was about 30 months in each arm—significantly lower than seen in most GOG trials—the benefit of neoadjuvant chemotherapy is being further studied in randomized trials. Optimal Use of Bevacizumab in the

1 ECOG 5202 was a randomized phase III study of oxaliplatin and 5-FU/leucovorin with or without bevacizumab for the treatment of patients who had undergone surgery for stage II colon cancer, stratified according to MSI status and 18q

improve results with PDT, hypothesized Dr. Gomer. He shared his results with bevacizumab (Avastin), a VEGF inhibitor, in combination with PDT in a Kapsoi sarcoma tumor model. 4 Gomer and Ferrario 4 found that combining PDT with bevacizumab resulted in a

NCCN Guidelines for Breast Cancer Updated; Bevacizumab Recommendation Affirmed The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines) for Breast Cancer to affirm

. Patients should be tested for all RAS mutations to identify patients who will benefit from anti-EGFR agents. Chemotherapy plus either bevacizumab or EGFR antibodies are both viable options as first-line therapy in patients with RAS wild-type mutations

cancers: platinum-based intravenous chemotherapy, platinum-based IV/IP chemotherapy, and platinum-based IP chemotherapy plus bevacizumab, as outlined in Table 2 . Specific options and supporting data for each of these categories of treatment are described

leucovorin. Concomitant vascular endothelial growth factor receptor inhibitor (VEGFi) therapies administered were bevacizumab (BEV) or ramucirumab (RAM), depending on the trial. Concomitant PPIs used were esomeprazole, lansoprazole, omeprazole, pantoprazole